Hair Growth Supplement

Nutrafol Men Hair Growth Nutraceutical

31 adverse event reports submitted to the FDA · 2024–2025 · Data current as of June 3, 2026

These are reports submitted to the FDA. A report does not mean the product caused the effect. Counts reflect reporting activity, not how common an effect is.

Most Reported Reactions

Top 10 reactions from 31 reports. One report may include multiple reactions — reaction totals may exceed the report count.

Hepatic enzyme increased

Nephrolithiasis

Renal failure

Jaundice

Alanine aminotransferase increased

Aspartate aminotransferase increased

Adverse reaction

Blood potassium increased

Arrhythmia

Heart rate increased

Reported Outcomes

Outcome categories as recorded in FDA reports. One report may include multiple outcomes.

Outcome	Reports
Other Serious or Important Medical Event	29
Hospitalization	10
Visited Emergency Room	7
Other Serious Outcome	3
Visited a Health Care Provider	2

Who Reported

Reporter demographics where available. Many reports do not include age or gender data.

Age

Under 18

18–34

35–49

50–64

65–79

80+

Unknown

18 reports had age data; 13 unknown.

Gender

Male

Unknown/Not Reported

Reports by Year

Annual report counts from 2024–2025. Spike years may reflect recalls, media coverage, or litigation rather than changes in the product.

'24

'25

Hover bars for exact counts.

Context about this data: Reports concentrated in 2024–2025 (6 and 25 respectively), reflecting rapid growth in the men's hair loss supplement category — the same upward trajectory seen in Nutrafol Women's. Consistent with a product gaining market share rather than a filing event.

← View all Nutrafol products in FDA data

Data Source

This page presents data from the FDA's CFSAN Adverse Event Reporting System (CAERS) via the openFDA API. Reports are voluntary and unverified. The FDA has not concluded that this product caused any reported event.

View openFDA CAERS data ↗ · About our methodology · How to read this data